A previously unknown mechanism helps cancer cells selectively produce proteins that drive tumor growth—such as KRAS—in common cancers, according to new research from The University of Texas MD Anderson Cancer Center. The findings reveal that targeting a specific enzyme may improve responses to targeted therapies and help overcome treatment resistance.